Publications

2023

  1. GPR84-mediated signal transduction affects metabolic function by promoting brown adipocyte activity. Sun XN, An YA, Paschoal VA, de Souza CO, Wang MY, Vishvanath L, Bueno LM, Cobb AS, Nieto Carrion JA, Ibe ME, Li C, Kidd HA, Chen S, Li W, Gupta RK, Oh DY.  J Clin Invest. 2023 Dec 15; 133(24):e168992 
  2. Hepatic sialic acid synthesis modulates glucose homeostasis in both liver and skeletal muscle. Peng J, Yu L, Huang L, Paschoal VA, Chu H, de Souza CO, Varre JV, Oh DY, Kohler JJ, Xiao X, Xu L, Holland WL, Shaul PW, Mineo C.  Mol Meta. 2023 Dec;78:101812

     

2022

  1. Adipose tissue macrophages exert systemic metabolic control by manipulating local iron concentrations. Joffin N, Gliniak CM, Funcke JB, Paschoal VA, Crewe C, Chen S, Gordillo R, Kusminski CM, Oh DY, Geldenhuys WJ, Scherer PE. Nat Metab. 2022 Nov;4(11):1474-1494.
  2. GPR92 activation in islet macrophages controls β cell function in a diet-induced obesity model. de Souza CO, Paschoal VA, Sun XN, Vishvanath L, Zhang Q, Shao M, Onoda T, Chen S, Joffin N, Bueno LM, Gupta RK, Oh DY. J Clin Invest. 2022 Nov 1;132(21):e160097
  3. Deficient Caveolin-1 synthesis in adipocytes stimulates systemic insulin-independent glucose uptake via extracellular vesicles. Crewe C, Chen S, Bu D, Gliniak CM, Wernstedt Asterholm I, Yu XX, Joffin N, de Souza CO, Funcke JB, Oh DY, Varlamov O, Robino JJ, Gordillo R, Scherer PE. Diabetes. 2022 Dec 1;71(12)2496-2512

     

2020 - 2021

  1. Metabolic functions of G protein-coupled receptors and β-arrestin-mediated signaling pathways in the pathophysiology of type 2 Diabetes and obesity. de Souza CO, Sun XN, Oh DY. Front Endocrinol. 2021 Aug 23;12:715877
  2. Mitochondrial metabolism is a key regulator of the fibro-inflammatory and adipogenic stromal subpopulations in white adipose tissue. Joffin N, Paschoal VA, Gliniak CM, Crewe C, Elnwasany A, Szweda LI, Zhang Q, Hepler C, Kusminski CM, Gordillo R, Oh DY, Gupta RK, Scherer PE. Cell Stem Cell. 2021 Apr 1;28(4):702-717
  3. Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders. Paschoal VA, Oh DY. Adipocyte. 2020 Dec;9(1)649-652 
  4. Perivascular mesenchymal cells control adipose-tissue macrophage accrual in obesity. Shan B, Shao M, Zhang Q, Hepler C, Paschoal VA, Barnes SD, Vishvanath L, An YA, Jia L, Maladi VS, Strans DW, Gupta OT, Elmquist JK, Oh DY, Gupta RK. Nat Metab. 2022 Nov;2(11)1332-1349
  5. Positive reinforcing mechanism between GPR120 and PPARγ modulate insulin sensitivity. Paschoal VA, Walenta E, Talukdar S, Pessentheiner AR, Osborn O, Hah N, Chi TJ, Tye GL, Armando AM, Evans RM, Chi NW, Quehenberger O, Olefsky JM, Oh DY. Cell Metab. 2020 Jun 2;31(6)1173-1188
  6. Conditional knockout of kisspeptin signaling in brown adipose tissue increases metabolic rate and body temperature and lowers body weight. Tolson KP, Marooki N, De Bond JP, Walenta E, Stephens SBZ, Liaw RB, Savur R, Wolfe A, Oh DY, Smith JT, Kauffman AS. FASEB J. 2020 Jan;34(1)107-121
  7. TAZ is a negative regulator of PPARγ activity in adipocytes and TAZ deletion improves insulin sensitivity and glucose tolerance. El Quarrat D, Issac R, Lee YS, Oh DY, Wollam J, Lackey D, Riopel M, Bandyopadhyay G, Seo JB, Sampath-Kumar R, Olefsky JM. Cell Metab. 2020 Jan 7;31(1):162-173

     

2016 - 2019

  1. Adipocyte PU.1 knockout promotes insulin sensitivity in HFD-fed obese mice. Lackey DE, Reis FCG, Issac R, Sapata RC, El Quarrat D, Lee YS, Bandyopadhyay G, Ofrecio JM, Oh DY, Osborn O. Sci Rep. 2019 Oct 14;9(1):14779
  2. SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. Crewe C, Zhu Y, Paschoal VA, Joffin N, Ghaben AL, Gordillo R, Oh DY, Liang G, Horton JD, Scherer PE. JCI Insight. 2019 Jul 16; 5(15):e129397
  3. Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling. Ying W, Wollam J, Ofrecio JM, Bandyopadhyay G, El Quarrat D, Lee YS, Oh DY, Li P, Osborn O, Olefsky JM. J Clin Invest. 2017 Mar 1;127(3):1019-1030
  4. Hematopoietic-derived Galectin-3 causes cellular and systemic insulin resistance. Li P, Liu S, Lu M, Bandyopadhyay G, Oh DY, Immamura T, Johnson AMF, Sears D, Shen Z, Cui B, Kong L, Hou S, Liang X, Iovino S, Watkins SM, Wing W, Osborn O, Wollam J, Brenner M, Olefsky JM. Cell. 2016 Nov 3;167(4):973-984
  5. One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. Gao MH, Giamouridis D, Lai NC, Walenta E, Paschoal VA, Kim YC, Miyanohara A, Guo T, Liao M, Liu L, Tan Z, Ciaraldi TP, Schenk S, Bhargava A, Oh DY, Hammond HK. JCI Insight. 2016 Sep 22;1(15):e88322
  6. G protein-coupled receptors as targets for anti-diabetic therapeutics. Oh DY, Olefsky JM. Nat Rev Drug Discov. 2016 Mar;15(3):161-172